|
|
Aires Pharmaceuticals, Inc. is a privately-held clinical stage pharmaceutical company developing therapies to treat pulmonary disorders. Founded in December 2006 and funded by ProQuest Investments, the company has exclusive licenses to technology from the National Institutes of Health and the University of Cincinnati.
Aires Pharmaceuticals is developing a novel inhaled drug called Aironite™ that has been demonstrated in animal models to treat both adult and pediatric pulmonary hypertension. The first clinical trial of our drug to treat pulmonary hypertension has been completed. Aironite has received Orphan Drug status by the U.S. FDA for this indication. As a second product opportunity, Aires is also pursuing indications associated with the treatment of bacterial pulmonary infections.
| |
|
Our Team
